Asosiy kontentga oʻtish
AkademIndex

Xizmatlar

← Ishga qaytish

Ushbu ish iqtibos qilgan ishlar

292 ta ish

Ish: Nanoparticle-Based PCSK9 Inhibition in Viral Infections: Evaluating Clinical Limitations and Advancing Therapeutic Strategies

  1. Polymeric Nanoparticles for Drug Delivery

    Maximilian A. Beach, Umeka Nayanathara, Yanting Gao +4

    Sharh maqolaOchiq kirish20247 iqtibos
    ABI

  2. Current hurdles to the translation of nanomedicines from bench to the clinic

    Snežana Đorđević, María Medel Gonzalez, Inmaculada Conejos‐Sánchez +6

    Sharh maqola20215 iqtibos
    ABI

  3. The Evolving Future of PCSK9 Inhibitors

    Robert S. Rosenson, Robert A. Hegele, Sergio Fazio +1

    Sharh maqolaOchiq kirish20184 iqtibos
    ABI

  4. A Common PCSK9Haplotype, Encompassing the E670G Coding Single Nucleotide Polymorphism, Is a Novel Genetic Marker for Plasma Low-Density Lipoprotein Cholesterol Levels and Severity of Coronary Atherosclerosis

    Suet N. Chen, Christie M. Ballantyne, Antonio M. Gotto +3

    Maqola20054 iqtibos
    ABI

  5. Spotlight on therapeutic efficiency of green synthesis metals and their oxide nanoparticles in periodontitis

    Mohammad Kiarashi, Parham Mahamed, Nader Ghotbi +6

    MaqolaOchiq kirish20243 iqtibos
    ABI

  6. HIV Infection and the Risk of Acute Myocardial Infarction

    Matthew S. Freiberg, Chung-Chou H. Chang, Lewis H. Kuller +25

    Maqola20133 iqtibos
    ABI

  7. Recent advances in metal nanoparticles to treat periodontitis

    Kamyar Nasiri, Seyed Mohammad Reza Masoumi, Sara Amini +7

    Sharh maqola20233 iqtibos
    ABI

  8. The potential use of mesenchymal stem cells-derived exosomes as microRNAs delivery systems in different diseases

    Elham Oveili, Somayeh Vafaei, Haniyeh Bazavar +4

    Sharh maqola20233 iqtibos
    ABI

  9. Mesenchymal Stem Cell-based Scaffolds in Regenerative Medicine of Dental Diseases

    Mohammad Kiarashi, Hannaneh Bayat, Seyed Abbas Shahrtash +6

    Sharh maqola20243 iqtibos
    ABI

  10. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

    Marianne Abifadel, Mathilde Varret, Jean‐Pierre Rabès +23

    Maqola20033 iqtibos
    ABI

  11. Sequence Variations in <i>PCSK9,</i> Low LDL, and Protection against Coronary Heart Disease

    Jonathan C. Cohen, Eric Boerwinkle, Thomas H. Mosley +1

    Maqola20063 iqtibos
    ABI

  12. SARS-CoV-2 Omicron variant: recent progress and future perspectives

    Yao Fan, Xiang Li, Lei Zhang +3

    Sharh maqola20223 iqtibos
    ABI

  13. An overview on nanoparticle-based strategies to fight viral infections with a focus on COVID-19

    Saman Yasamineh, Hesam Ghafouri Kalajahi, Pooneh Yasamineh +10

    Sharh maqola20223 iqtibos
    ABI

  14. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial

    Kevin Fitzgerald, Maria Frank-Kamenetsky, Svetlana Shulga‐Morskaya +17

    MaqolaOchiq kirish20132 iqtibos
    ABI

  15. Mechanistic understanding of in vivo protein corona formation on polymeric nanoparticles and impact on pharmacokinetics

    Nicolas Bertrand, P. Grenier, Morteza Mahmoudi +7

    MaqolaOchiq kirish20172 iqtibos
    ABI

  16. New Approaches for Targeting PCSK9: Small-Interfering Ribonucleic Acid and Genome Editing

    Reindert F. Oostveen, Amit V. Khera, Sekar Kathiresan +5

    Sharh maqola20232 iqtibos
    ABI

  17. Lipid-based nanoparticle formulations for small molecules and RNA drugs

    Ludger M. Ickenstein, Patrick Garidel

    Sharh maqola20192 iqtibos
    ABI

  18. Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9)

    Rainer Schulz, Klaus‐Dieter Schlüter, Ulrich Laufs

    Sharh maqolaOchiq kirish20152 iqtibos
    ABI

  19. PCSK9 and LDLR degradation

    Thomas A. Lagace

    Sharh maqolaOchiq kirish20142 iqtibos
    ABI

  20. PCSK9 induces a pro-inflammatory response in macrophages

    Chiara Ricci, Massimiliano Ruscica, Marina Camera +10

    MaqolaOchiq kirish20182 iqtibos
    ABI

  21. PCSK9 and inflammation: a review of experimental and clinical evidence

    Amir Abbas Momtazi‐Borojeni, Sarvenaz Sabouri-Rad, Antonio M. Gotto +5

    Sharh maqolaOchiq kirish20192 iqtibos
    ABI

  22. Proprotein Convertase Subtilisin/Kexin Type 9

    Chiara Macchi, Nicola Ferri, Cesare R. Sirtori +3

    Sharh maqolaOchiq kirish20212 iqtibos
    ABI

  23. PCSK9-targeted therapies: present and future approaches

    Mahmoud Al Rifai, Christie M. Ballantyne

    Sharh maqola20212 iqtibos
    ABI

  24. May statins and PCSK9 inhibitors be protective from COVID-19 in familial hypercholesterolemia subjects?

    Roberto Scicali, Antonino Di Pino, Salvatore Piro +2

    Sharh maqolaOchiq kirish20202 iqtibos
    ABI

  25. Statins and PCSK9 inhibitors: What is their role in coronavirus disease 2019?

    Fotios Barkas, Haralampos Milionis, Georgia Anastasiou +1

    Sharh maqolaOchiq kirish20202 iqtibos
    ABI